Washington, D.C./ Politics & Govt

House Panel Weighs Psychedelic Therapy for Veterans as Suicides Stay Flat

AI Assisted Icon
Published on November 21, 2026
House Panel Weighs Psychedelic Therapy for Veterans as Suicides Stay FlatCannon House Office Building — Site of Veterans’ Affairs Hearing
Google Street View

Lawmakers on the House Veterans' Affairs Subcommittee on Health spent roughly two and a half hours Wednesday pressing VA officials on whether the department is actually ready to deliver psychedelic-assisted therapy to veterans if federal regulators approve it. The hearing, titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward,” focused on a VA estimate that approximately 180,000 veterans might qualify for treatment with compounds like MDMA, psilocybin, LSD, DMT and ibogaine under preliminary screening criteria — a figure VA officials stressed is not the same as confirmed eligibility for an approved treatment.

A Bipartisan Push Rooted in Stagnant Suicide Numbers

Subcommittee Chair Rep. Mariannette Miller-Meeks, an Iowa Republican, Army veteran and ophthalmologist who recently lost her reelection bid, opened the hearing by framing the issue in blunt terms, according to reporting from Marijuana Moment. She said “emerging research into substances such as MDMA and psilocybin has shown promise for treating PTSD, treatment-resistant depression, and other serious mental health conditions,” and told colleagues that conversations with veterans convinced her these therapies could offer hope. Miller-Meeks pointed to the VA's suicide prevention annual report, published in September, which found nearly 6,500 veterans died by suicide in 2024, arguing that change is needed because those figures have remained stagnant.

Rep. Julia Brownley struck a more cautious tone, calling ongoing VA clinical trials welcome news that could improve lives while warning the treatments will not be a panacea for everyone, and particularly not for every veteran, per the same Marijuana Moment account. She said the VA must maintain and strengthen its broader mental-healthcare continuum rather than treating psychedelics as a cure-all, and she raised concern that VA staff reductions could hinder implementation of new treatments. Brownley also pressed officials on whether the department would hire additional staff to meet demand without overtaxing its existing workforce if treatments win approval within the next several months.

Ten Sites Identified, but Not Disclosed

VA senior adviser Andrew Gradison testified that the department has already identified 10 facilities with the expertise, physical space and operational capacity needed to serve as early implementers, educators or sites-in-training, as reported by Marijuana Moment. Gradison called psychedelic treatments extremely labor intensive and said the VA has analyzed staffing needs in an effort to resource those initial sites without harming broader mental-health access elsewhere in the system. He declined to disclose every site location publicly but committed to providing a full list to all committee members within 30 days.

Rep. Herb Conaway, a New Jersey Democrat and physician, said most of the selected sites are concentrated on the coasts, naming California, New Haven, Connecticut, and New York among the locations on the list, and noted that it included no sites in the Southeast. Ilse Wiechers, the VA's deputy assistant under secretary for health for patient care services, said the chosen sites were evaluated as most likely to implement treatment successfully early on, and that the department will draw on their experience as it plans to expand beyond its initial facilities once clinicians receive training, Army Times reported.

Scale of the Need Versus Scale of the Plan

Beyond the 180,000 figure tied to preliminary screening, VA officials said approximately 2.1 million veterans receiving VA healthcare carry diagnoses involving PTSD, major depressive disorder or treatment-resistant depression — though the two figures measure different things and were not presented as directly comparable. The department's research protocols currently call for preparation, supervised dosing sessions lasting six to eight hours, and follow-up treatment, according to the same Army Times account. That report also noted the VA's fiscal 2027 budget included no dedicated funding request to implement the treatments, even as the department said it was conducting active clinical studies on psychedelics to treat mental-health conditions — a figure Marijuana Moment put at 21 studies, while Becker's Behavioral Health separately reported the VA was involved in 20 psychedelic clinical trials.

Army Times also cited a September VA inspector general report finding that 58% of reporting VA facilities identified severe shortages of psychologists, a staffing gap that loomed over the hearing's discussion of whether the department could scale up psychedelic programs. VA officials said they discouraged veterans from self-medicating with psychedelics or using them to replace other mental-health treatment options, a caution Marijuana Moment noted was repeated throughout the session.

Regulatory Barriers and the Path to Approval

Rep. Jack Bergman, a Michigan Republican and retired Marine Corps lieutenant general, asked officials how the VA should coordinate with the Drug Enforcement Administration and where controlled-substance requirements might cause delays, pointing to the fact that the psychedelic drugs under review remain classified as Schedule I substances under federal law. Marion Coe, director of clinical development and postmarketing surveillance at Pinney Associates, Inc., told the panel that research and legal storage of the compounds involve a complicated process, and said the VA and DEA should cooperate to reduce bureaucratic barriers to research. Coe added that federal approval and rescheduling would simplify that process considerably.

The regulatory backdrop traces to an April 2026 executive order in which President Donald Trump directed the FDA to work with the VA, DEA and HHS to remove barriers to testing psychedelic treatments, targeting obstacles including drug-enforcement classification, according to Stars and Stripes. The FDA has said several psychedelic drugs could move toward potential approval in 2027 following that order, and Stars and Stripes reported that VA facilities in Rhode Island and Connecticut began randomized clinical trials of MDMA-assisted therapies this year, building on VA trial funding allocated in 2024. No classic psychedelic drug has received FDA approval for treating mental illness, though Becker's Behavioral Health reported that Compass Pathways anticipates approval of its synthetic psilocybin treatment during the first half of 2027.

Veterans Groups Push for Faster Access

Groups including the Veterans of Foreign Wars, Special Forces Foundation and Disabled American Veterans are urging lawmakers to accelerate clinical research into psychedelic-assisted therapy and remove barriers to access, Stars and Stripes reported. VA officials reiterated that the department is making early preparations to provide therapies that are approved by the FDA for clinical use, though no such approval currently exists. Stars and Stripes also pointed to a 2024 Stanford study of 30 veterans with traumatic brain injuries from repeated blast exposures, in which nearly 90% showed improvements after receiving ibogaine — a comparison lawmakers cited as evidence of the stakes involved as the committee awaits the VA's promised list of sites next month.